Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is on track to potentially revolutionize the treatment of depression, with a strong focus on their proprietary inhalable and injectable mebufotenin products. Their recent financial results have demonstrated increasing cash reserves, providing strategic support for their planned end-of-phase 2 regulatory alignment and Phase 3 initiation and execution. The company has also garnered positive attention in the medical community with peer-reviewed publications and ongoing medical meeting presence, which further reinforces the potential of their lead product, GH001, in treating TRD.

Bears say

GH Research is still in the early stages of development and their portfolio currently consists of only two products. However, the results from their Phase 2b trial and the additional funding they received in April ($378 million) support their potential to be a major player in the psychiatry field as they work towards introducing transformative psychedelic therapies. Despite this, GH Research is keeping details of their proprietary aerosolized device and dosing regimen confidential for competitive reasons, which may hinder investor confidence and limit their success in the long term.

GHRS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 6 analysts, GHRS has a Buy consensus rating as of Jul 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.